Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02929615
Recruitment Status : Unknown
Verified October 2016 by Jun Zhu, Peking University. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 65 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with relapse and refractory lymphoma and multiple myeloma.
At least 1 measurable lesions and its size≥15mm.
Patients ≤65 years，no limitations for both gender.